Patients in the experimental group of ND0612 demonstrated favourable efficacy over IR-LD/CD. Data showed a statistically significant increase (p<0.0001) of 1.72 hours in “ON” time without troublesome dyskinesia. The trial also demonstrated positive and clinically meaningful results for the first four secondary endpoints, including a reduction of “OFF” time (p<0.0001).
Mitsubishi Tanabe Pharma Corporation has ... - Cure Parkinson's
Mitsubishi Tanabe Pharma Corporation has announced that a Phase III trial of its Parkinson’s disease candidate has met its primary endpoint.
Written by
Farooqji
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
several posts have been made regarding the exanatide trials, but I just stumbled across this brief...
Cuban drug for Parkinson’s and Alzheimer’s diseases moves to phase III
conducting the phase IV clinical trial are being trained, aspire to include 1,456.
NeuralCIM, which
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
individuals with early, untreated Parkinsons.
- The primary endpoint, change from baseline in the...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
Phase 3 clinical study of Buntanetap (Posiphen) in individuals recently diagnosed with #Parkinsons...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
prnewswire.com/news-releases/annovis-bio-announces-approval-for-european-union-clinical-trial-sites-
Phase 3 Positive Topline Results for Tavapadon 
Benfotiamine In The Mix For PD Again? 
Virtual Reality Training Improves Balance for Patients With Parkinson Disease
Has anyone tried hydrogen water for PD?
